-- Mountain Province Diamonds (MPVD.TO) 周五宣布，已延长其定期贷款的到期日和营运资金贷款的本金偿还日期。 根据与 Dunebridge Worldwide 达成的第四次修订协议，4000 万美元定期贷款的到期日和 3300 万美元营运资金贷款的本金偿还日期均从 4 月 30 日延至 6 月 30 日。 Mountain Province 还出售了其在西北地区 Gahcho Kue 矿的钻石股份，所得款项为 999,999 美元，总价 833,000 美元。 这些资金将为 Mountain Province 提供短期运营所需的资金，以支持其在评估战略选择的同时继续运营。 此外，Mountain Province 于周四晚间公布，其第一季度钻石产量同比增长。 该公司回收了200万克拉钻石，较去年同期的762,978克拉增长了163%。 第一季度钻石销售总量为858,173克拉，价值4000万加元，平均每克拉47加元。去年同期，该公司钻石销售总量为426,268克拉，价值4400万加元，平均每克拉103加元。 “钻石市场持续受到地缘政治不确定性的不利影响，包括对美国关税和中东持续冲突的担忧，”总裁兼首席执行官乔纳森·科默福德表示。 “正如之前报道的那样，我们继续与所有利益相关者进行建设性沟通，以应对市场目前面临的严峻挑战。尽管如此，我们目前在钻石回收量方面取得了非常强劲的业绩，”科默福德说道。 与此同时，杰夫·斯威诺加因兼任其他多个董事会职务而辞去了董事职务。
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
Australia
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
$GSK
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.